Inventor

GOLDENBERG DAVID M

US375 patents

⚠️ This page may combine multiple inventors who share the name “GOLDENBERG DAVID M”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

GOLDENBERG DAVID M

IMMUNOMEDICS INC

Immunoconjugates with an intracellularly-cleavable linkage

Internalizing anti-CD74 antibodies and methods of use

Internalizing anti-CD74 antibodies and methods of use

Antibody therapy

Camptothecin-binding moiety conjugates

Chimeric, human and humanized anti-granulocyte antibodies and methods of use

Internalizing anti-CD74 antibodies and methods of use

Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof

Anti-CD20 antibodies and fusion proteins thereof and methods of use

Humanized anti-CD19 antibodies

Immunotherapy of autoimmune disorders using antibodies which target B-cells

Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells

Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Immunotherapy of B-cell malignancies using anti-CD22 antibodies

Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments

Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype

Detection and therapy of lesions with biotin/avidin conjugates

Antibody-drug conjugates and uses thereof

Humanized anti-HLA-DR antibodies

Immunoconjugates with an intracellularly-cleavable linkage

Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity

Humanized L243 antibodies

Immunoconjugates with an intracellularly-cleavable linkage

CHANG CHIEN-HSING

Tetrameric cytokines with improved biological activity

Dock-and-lock (DNL) complexes for delivery of interference RNA

Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapy

Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases

Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in VIVO

Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology

PEGylation by the dock and lock (DNL) technique

Methods and compositions for generating bioactive assemblies of increased complexity and uses

Multivalent immunoglobulin-based bioactive assemblies

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses

Dimeric alpha interferon PEGylated site-specifically shows enhanced and prolonged efficacy in vivo

IBC PHARMACEUTICALS INC

Methods and compositions for generating bioactive assemblies of increased complexity and uses

PEGylation by the dock and lock (DNL) technique

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses

Methods and compositions for generating bioactive assemblies of increased complexity and uses

Multivalent immunoglobulin-based bioactive assemblies

Stably tethered structures of defined compositions with multiple functions or binding specificities

T-cell redirecting bispecific antibodies for treatment of disease

Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases

Tetrameric cytokines with improved biological activity

GOVINDAN SERENGULAM V

Immunoconjugates with an intracellularly-cleavable linkage

Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases

Camptothecin-binding moiety conjugates

RS7 antibodies

GOLDENBERG DAVID M

Humanized anti-HLA-DR antibodies

Humanized L243 antibodies

Immunotherapy of B-cell malignancies using anti-CD22 antibodies